A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.

Lockwood GM, Pinkerton SM, Barlow DH

Human reproduction (Oxford, England)1 Feb 1995Cited by 13 (Europe PMC)

PMID7769051DOI10.1093/oxfordjournals.humrep.a135930PepBankPUB-07769051

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In IVF patients, pregnancy per recruit was 23% with nafarelin 200 micrograms versus 31% with buserelin, without a significant difference.
In plain wordsIn IVF patients, nafarelin 200 micrograms produced a 23% pregnancy rate per recruit, without a significant difference from buserelin.
Peptide
Nafarelin
Outcome
DecreaseClinical pregnancy per recruit
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasalAs given in this study (human).
Measurements
Clinical pregnancy rate per recruit
23%
nafarelin 200 micrograms
Clinical pregnancy rate per recruit
31%
buserelin 200 micrograms
Source sentences
Summary
The rates for nafarelin 200 micrograms were 23 and 37% respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
There was no statistically significant difference in pregnancy rates, by either drug or dosage.
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
Nafarelin 400 micrograms and buserelin 200 micrograms both produced clinical pregnancy rates of 31% per recruit and 39% per embryo transfer.
Report a problemFND-0776905103
02HumanRandomized controlled trialEfficacy outcome
In IVF patients, pregnancy per embryo transfer was 37% with nafarelin 200 micrograms versus 39% with buserelin, without a significant difference.
In plain wordsIn IVF patients, pregnancy rates per embryo transfer did not differ significantly between nafarelin 200 micrograms and buserelin.
Peptide
Nafarelin
Outcome
DecreaseClinical pregnancy per embryo transfer
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasalAs given in this study (human).
Measurements
Clinical pregnancy rate per embryo transfer
37%
nafarelin 200 micrograms
Clinical pregnancy rate per embryo transfer
39%
buserelin 200 micrograms
Source sentences
Summary
The rates for nafarelin 200 micrograms were 23 and 37% respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
There was no statistically significant difference in pregnancy rates, by either drug or dosage.
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
Nafarelin 400 micrograms and buserelin 200 micrograms both produced clinical pregnancy rates of 31% per recruit and 39% per embryo transfer.
Report a problemFND-0776905104
03HumanRandomized controlled trialEfficacy outcome
In IVF patients, pituitary down-regulation took significantly longer with nafarelin 200 micrograms than buserelin.
In plain wordsIn IVF patients, pituitary suppression took longer with nafarelin 200 micrograms than buserelin.
Peptide
Nafarelin
Outcome
IncreaseTime to pituitary down-regulation
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasalAs given in this study (human).
Source sentences
Summary
The time taken for pituitary down-regulation to be achieved was significantly longer on nafarelin 200 micrograms than on either nafarelin 400 micrograms or buserelin.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905106
04HumanRandomized controlled trialEfficacy outcome
In IVF patients, stimulation with human menopausal gonadotrophin required significantly fewer days with nafarelin 200 micrograms than buserelin.
In plain wordsIn IVF patients, stimulation required fewer days with nafarelin 200 micrograms than buserelin.
Peptide
Nafarelin
Outcome
DecreaseStimulation duration
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasalAs given in this study (human).
Source sentences
Summary
The total number of days stimulation with human menopausal gonadotrophin required to reach criteria for human chorionic gonadotrophin (HCG) administration was significantly longer on buserelin than on either dose of nafarelin.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905108
05HumanRandomized controlled trialEfficacy outcome
In IVF patients, median serum oestradiol at HCG administration was significantly higher with nafarelin 200 micrograms than buserelin.
In plain wordsIn IVF patients, blood estrogen at HCG administration was higher with nafarelin 200 micrograms than buserelin.
Peptide
Nafarelin
Outcome
IncreaseSerum oestradiol at HCG administration
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasalAs given in this study (human).
Source sentences
Summary
Median serum oestradiol concentrations on the day of HCG administration were significantly higher on either dose of nafarelin than on buserelin.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905110
06HumanNon-randomized trialEfficacy outcome
In IVF patients, nafarelin 400 micrograms and buserelin each produced a clinical pregnancy rate of 31% per recruit, without significant difference.
In plain wordsIn IVF patients, pregnancy rates per recruit were 31% with both nafarelin 400 micrograms and buserelin.
Peptide
Nafarelin
Outcome
No significant changeClinical pregnancy per recruit
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms twice daily · intranasalAs given in this study (human).
Measurements
Clinical pregnancy rate per recruit
31%
nafarelin 400 micrograms
Clinical pregnancy rate per recruit
31%
buserelin 200 micrograms
Source sentences
Summary
Nafarelin 400 micrograms and buserelin 200 micrograms both produced clinical pregnancy rates of 31% per recruit and 39% per embryo transfer.
4 context sentences(design, population, supporting numbers)
Summary · context
There was no statistically significant difference in pregnancy rates, by either drug or dosage.
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905101
07HumanNon-randomized trialEfficacy outcome
In IVF patients, nafarelin 400 micrograms and buserelin each produced a clinical pregnancy rate of 39% per embryo transfer, without significant difference.
In plain wordsIn IVF patients, pregnancy rates per embryo transfer were 39% with both nafarelin 400 micrograms and buserelin.
Peptide
Nafarelin
Outcome
No significant changeClinical pregnancy per embryo transfer
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms twice daily · intranasalAs given in this study (human).
Measurements
Clinical pregnancy rate per embryo transfer
39%
nafarelin 400 micrograms
Clinical pregnancy rate per embryo transfer
39%
buserelin 200 micrograms
Source sentences
Summary
Nafarelin 400 micrograms and buserelin 200 micrograms both produced clinical pregnancy rates of 31% per recruit and 39% per embryo transfer.
4 context sentences(design, population, supporting numbers)
Summary · context
There was no statistically significant difference in pregnancy rates, by either drug or dosage.
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905102
08HumanNon-randomized trialEfficacy outcome
In IVF patients, pregnancy per recruit was 31% with nafarelin 400 micrograms versus 23% with 200 micrograms, without a significant difference.
In plain wordsIn IVF patients, pregnancy per recruit was 31% with nafarelin 400 micrograms versus 23% with 200 micrograms, without a significant difference.
Peptide
Nafarelin
Outcome
IncreaseClinical pregnancy per recruit by dose
Study
n: not reported in source
Comparator
Nafarelin 200 micrograms twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms twice daily · intranasalAs given in this study (human).
Measurements
Clinical pregnancy rate per recruit
31%
nafarelin 400 micrograms
Clinical pregnancy rate per recruit
23%
nafarelin 200 micrograms
Source sentences
Summary
Nafarelin 400 micrograms and buserelin 200 micrograms both produced clinical pregnancy rates of 31% per recruit and 39% per embryo transfer.
4 context sentences(design, population, supporting numbers)
Summary · context
The rates for nafarelin 200 micrograms were 23 and 37% respectively.
Summary · context
There was no statistically significant difference in pregnancy rates, by either drug or dosage.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905105
09HumanNon-randomized trialEfficacy outcome
In IVF patients, pituitary down-regulation took significantly longer with nafarelin 200 micrograms than 400 micrograms.
In plain wordsIn IVF patients, pituitary suppression took longer with nafarelin 200 micrograms than 400 micrograms.
Peptide
Nafarelin
Outcome
IncreaseTime to pituitary down-regulation by dose
Study
n: not reported in source
Comparator
Nafarelin 400 micrograms twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasalAs given in this study (human).
Source sentences
Summary
The time taken for pituitary down-regulation to be achieved was significantly longer on nafarelin 200 micrograms than on either nafarelin 400 micrograms or buserelin.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905107
10HumanNon-randomized trialEfficacy outcome
In IVF patients, stimulation with human menopausal gonadotrophin required significantly fewer days with nafarelin 400 micrograms than buserelin.
In plain wordsIn IVF patients, stimulation required fewer days with nafarelin 400 micrograms than buserelin.
Peptide
Nafarelin
Outcome
DecreaseStimulation duration
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms twice daily · intranasalAs given in this study (human).
Source sentences
Summary
The total number of days stimulation with human menopausal gonadotrophin required to reach criteria for human chorionic gonadotrophin (HCG) administration was significantly longer on buserelin than on either dose of nafarelin.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905109
11HumanNon-randomized trialEfficacy outcome
In IVF patients, median serum oestradiol at HCG administration was significantly higher with nafarelin 400 micrograms than buserelin.
In plain wordsIn IVF patients, blood estrogen at HCG administration was higher with nafarelin 400 micrograms than buserelin.
Peptide
Nafarelin
Outcome
IncreaseSerum oestradiol at HCG administration
Study
n: not reported in source
Comparator
Buserelin 200 micrograms five times daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms twice daily · intranasalAs given in this study (human).
Source sentences
Summary
Median serum oestradiol concentrations on the day of HCG administration were significantly higher on either dose of nafarelin than on buserelin.
3 context sentences(design, population, supporting numbers)
Summary · context
In this prospective study, the efficacy and safety of intranasal nafarelin and buserelin as adjunctive therapy during IVF were assessed.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905111
12HumanNon-randomized trialEfficacy outcome
In IVF patients, pregnancy per embryo transfer was 39% with nafarelin 400 micrograms versus 37% with 200 micrograms, without a significant difference.
In plain wordsIn IVF patients, pregnancy per embryo transfer was 39% with nafarelin 400 micrograms versus 37% with 200 micrograms, without a significant difference.
Peptide
Nafarelin
Outcome
IncreaseClinical pregnancy per embryo transfer by dose
Study
n: not reported in source
Comparator
Nafarelin 200 micrograms twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms twice daily · intranasalAs given in this study (human).
Measurements
Clinical pregnancy rate per embryo transfer
39%
nafarelin 400 micrograms
Clinical pregnancy rate per embryo transfer
37%
nafarelin 200 micrograms
Source sentences
Summary
Nafarelin 400 micrograms and buserelin 200 micrograms both produced clinical pregnancy rates of 31% per recruit and 39% per embryo transfer.
4 context sentences(design, population, supporting numbers)
Summary · context
The rates for nafarelin 200 micrograms were 23 and 37% respectively.
Summary · context
There was no statistically significant difference in pregnancy rates, by either drug or dosage.
Summary · context
A total of 240 female patients were recruited to the study and in the first phase patients were randomized to receive either intranasal nafarelin 200 micrograms twice daily or buserelin 200 micrograms five times daily.
Summary · context
In the second phase, patients received either nafarelin 400 micrograms twice daily or buserelin 200 micrograms five times daily.
Report a problemFND-0776905112

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.